|
|
|
FDA Home | Search FDA Site | A-Z Index | Contact FDA
| Center | Date | Time | Location* |
|---|---|---|---|
| CBER | March 18, 2003 | 10:30 a.m. - 12:45 p.m. | Food and Drug
Administration |
Agenda:
The committee will review and discuss the selection of strains to be included
in the influenza virus vaccine for the 2003–2004 season.
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by March 12, 2003. Oral presentations from the public will be
scheduled between approximately 11:30 a.m. to 12:30 p.m. Time allotted for each
presentation may be limited. Those desiring to make formal oral presentations
should notify the contact person before March 12, 2003, and submit a brief statement
of the general nature of the evidence or arguments they wish to present, the
names and addresses of proposed participants, and an indication of the approximate
time requested to make their presentation. Persons attending FDA’s advisory
committee meetings are advised that the agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Jody G. Sachs or Denise H. Royster at least 7 days in advance of the meeting.
Contact Person:
Jody G. Sachs or Denise H. Royster, Food and Drug Administration, Center for
Biologics Evaluation and Research (HFM–71), 301–827–0314,
or FDA Advisory Committee Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC area), code 12391. Please call
the Information Line for up-to-date information on this meeting.